ArticleNature2024
Mechanisms of action and resistance in histone methylation-targeted therapy.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
23.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Association BetweenPathogens (Basel, Switzerland) · 2025Pooled it
- Article
- Article
- 5-hydroxymethylcytosine deposition mediates Polycomb repressive complex 2 function iniScience · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- Histone modifications across cancers: mechanisms, therapy and clinical translation.Molecular cancer · 2026Review
- UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications.Epigenomes · 2026Review
- HTLV-1 Tax Reshapes the DNA-Binding Pattern of Transcription Factor IRF4 and Disrupts Host Gene Regulation.Cancer science · 2026Article
- Histone methylation defines c-Jun/Sox2/Hif1α axis that controls stemness and tumor progression in squamous cell carcinoma.Nature communications · 2026Article
- Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer.Biomolecules · 2026Review
- Recent progress in T-cell malignancies including adult T-cell leukemia-lymphoma.International journal of hematology · 2026Article
- Genome-epigenome crosstalk in T-cell lymphomas: from maps to mechanisms.International journal of hematology · 2026Review
- Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV.International journal of hematology · 2026Review
- Structural landscape of H3K27me3 recognition by protein domains and their potential for inhibition.The Journal of biological chemistry · 2026Review
- Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Translating tumor epigenetic subtyping into methylome network-based prognostic models in early-stage NSCLC: results from the prospective MOBIT study.Journal of translational medicine · 2026Article
- From mechanism to clinic: a panoramic perspective on targeting HMOX1 to overcome drug resistance.Journal of cancer research and clinical oncology · 2026Review
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.Nature communications · 2026Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 1 country.
Makoto Yamagishi *Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. myamagishi@edu.k.u-tokyo.ac.jp.ORCID 0000-0002-8142-4686
Yuta Kuze *Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Seiichiro KobayashiDivision of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Makoto NakashimaLaboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Satoko MorishimaDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.ORCID 0000-0002-7391-4271
Toyotaka KawamataDepartment of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-1311-8756
Junya MakiyamaDepartment of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0883-2920
Kako SuzukiLaboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Masahide SekiLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-6091-8698
Kazumi AbeLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Kiyomi ImamuraLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Eri WatanabeIMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kazumi TsuchiyaIMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Isao YasumatsuOrganic and Biomolecular Chemistry Department, Daiichi Sankyo RD Novare, Tokyo, Japan.ORCID 0009-0000-9865-4835
Gensuke TakayamaTranslational Science I, Daiichi Sankyo, Tokyo, Japan.
Yoshiyuki HizukuriTranslational Science I, Daiichi Sankyo, Tokyo, Japan.
Kazumi ItoTranslational Science I, Daiichi Sankyo, Tokyo, Japan.
Yukihiro TairaLaboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yasuhito NannyaDivision of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Arinobu TojoTokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0001-9016-1948
Toshiki WatanabeDepartment of Practical Management of Medical Information, Graduate School of Medicine, St Marianna University, Kanagawa, Japan.
Shinji TsutsumiTranslational Science I, Daiichi Sankyo, Tokyo, Japan.
Yutaka SuzukiLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ysuzuki@edu.k.u-tokyo.ac.jp.ORCID 0000-0003-4852-1879
Kaoru UchimaruLaboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. uchimaru@edu.k.u-tokyo.ac.jp.ORCID 0000-0002-1665-9606
The University of Tokyo · JPDaiichi-Sankyo (Japan) · JPUniversity of Tokyo Hospital · JPSasebo City General Hospital · JPSt. Marianna University School of Medicine · JPTokyo Medical and Dental University · JPUniversity of the Ryukyus · JPYokohama Rosai Hospital · JP
Funding
AMEDJSPS KAKENHI
Abstract
Epigenomes enable the rectification of disordered cancer gene expression, thereby providing new targets for pharmacological interventions. The clinical utility of targeting histone H3 lysine trimethylation (H3K27me3) as an epigenetic hallmark has been demonstrated
Indexed as
HistonesLeukemia-Lymphoma, Adult T-CellMethylationAdultChromatinDioxygenasesDNA-Binding ProteinsDNA MethylationDNA Methyltransferase 3ADrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGenes, Tumor SuppressorHomeostasisHumansLysineChromatinDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3ADNMT3A protein, humanEnhancer of Zeste Homolog 2 ProteinEZH1 protein, humanEZH2 protein, humanHistonesLysinePolycomb Repressive Complex 2TET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.